Pluripotent stem cell, pharmaceutical composition, and preparation method and application thereof

A pluripotent stem cell, stem cell technology, applied in the directions of drug combination, biochemical equipment and method, pharmaceutical formulation, etc., can solve the problems of inability to apply clinically, low induction efficiency, long induction time, etc.

Pending Publication Date: 2021-03-23
BEIJING INST FOR STEM CELL & REGENERATIVE MEDICINE +1
View PDF16 Cites 28 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In recent years, many studies have reported methods for inducing mesenchymal-like cells from human embryonic stem cells. However, there are still shortcomings such as low induction efficiency, complicated induction process, and long induction time, and most of the methods require the use of heterogeneous cells such as serum. Substances that cannot be used clinically

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pluripotent stem cell, pharmaceutical composition, and preparation method and application thereof
  • Pluripotent stem cell, pharmaceutical composition, and preparation method and application thereof
  • Pluripotent stem cell, pharmaceutical composition, and preparation method and application thereof

Examples

Experimental program
Comparison scheme
Effect test

preparation example 1

[1303] Preparation Example 1: Preparation of M cells derived from human embryonic stem cells

[1304] 1.1 Generation of embryoid bodies (EBs)

[1305] a. Remove the original culture medium and add PBS to wash;

[1306] b. Use Dispase to digest human embryonic stem cells (Q-CTS-hESC-2, National Stem Cell Resource Bank);

[1307] c. Discard the enzyme solution, add 1ml of KO-DMEM / F12, and draw a vertical well;

[1308] d. Moisten the tip of the gun, suck the liquid in the six-hole plate and transfer it to a 15ml centrifuge tube for centrifugation;

[1309] e. Remove the supernatant from the centrifuged clones, resuspend the cells in a small amount of EB culture medium in a culture dish, add them to a low-attachment culture dish (Corning: Cat. No. 3262), and culture in a 37°C incubator.

[1310] Preparation of EB culture fluid (first medium): add 10% (v / v) of KOSR, 1% (v / v) of NEAA (ie, 0.1mM), 1% (v / v) of KO-DMEM to KO-DMEM ) of GlutaMAX (ie, 2 mM), 8 ng / mL of bFGF, and 0....

Embodiment 1-1

[1379] Example 1-1: Detection of surface markers of M cells

[1380] Detect the expression situation of the M cell surface protein of Preparation Example 1 by flow cytometry:

[1381] 1. Discard the culture supernatant, wash it once with PBS, add Trypsin to digest for 3-5min, and add PBS to stop.

[1382] 2. Collect the cell suspension and centrifuge at 1200rpm for 3min.

[1383] 3. Discard the supernatant, resuspend with PBS, and filter with a cell sieve to remove cell clusters, count, and count as 2×10 per tube. 6 Subpackage.

[1384] 4. Centrifuge at 1200rpm for 3min.

[1385] 5. After blocking with 2% BSA blocking solution for 20 minutes, centrifuge at 1200 rpm for 3 minutes.

[1386] 6. Discard the supernatant, resuspend the cells with 100 μL of 1% BSA antibody diluent, add the direct-labeled antibody, and incubate at room temperature for 30-45 minutes.

[1387] 7. Wash three times with 1mL PBS, centrifuge at 1200rpm for 3min, and discard the supernatant.

[1388] 8...

Embodiment 1-2

[1392] Example 1-2: Detection of cytokine expression levels in M ​​cells

[1393] The expression levels of cytokines in the M cells of Preparation Example 1 were measured by Real-time PCR.

[1394] 1. Extraction of cellular RNA

[1395] Use the RNA extraction kit to extract, the specific steps are as follows:

[1396] (1) Add 10 μL of β-mercaptoethanol to each ml of RL lysate, and lyse the cells on ice according to the amount of cells;

[1397] (2) Transfer the lysed liquid to the CS column, centrifuge at 12000rpm for 2min;

[1398] (3) Add 1 volume of 70% ethanol to the filtrate, mix well and transfer to CR3, centrifuge at 12000rpm for 1min;

[1399] (4) Pour off the filtrate, add 350 μL RW1 to CR3, centrifuge at 12000 rpm for 1 min;

[1400] (5) Pour off the filtrate, add 80 μL DNase I working solution to CR3, room temperature for 15 minutes;

[1401] (6) Add 350 μL RW1 to CR3, centrifuge at 12000 rpm for 1 min;

[1402] (7) Pour off the filtrate, add 500 μL RW to CR3,...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
thicknessaaaaaaaaaa
thicknessaaaaaaaaaa
Login to view more

Abstract

The invention relates to the field of cell therapy. Specifically, the invention relates to a method for producing a mesenchymal stem cell population, a mesenchymal stem cell population produced by themethod and a culture supernatant thereof, and a pharmaceutical composition comprising such cells or a culture supernatant thereof. The invention also relates to the mesenchymal stem cell population and a culture supernatant thereof, and uses of the mesenchymal stem cell population and the culture supernatant in prevention and treatment of diseases.

Description

technical field [0001] The present invention relates to the field of cell therapy. Specifically, the present invention relates to a method for producing a population of mesenchymal stem cells, a population of mesenchymal stem cells produced by said method and a culture supernatant thereof, and a pharmaceutical composition comprising such cells or a culture supernatant thereof. The present invention also relates to the mesenchymal stem cell population and its culture supernatant, as well as the use of such cells or its culture supernatant for preventing and / or treating diseases. Background technique [0002] Mesenchymal stem cells (MSCs) are adult stem cells with self-replication ability and multi-directional differentiation potential, which can be obtained from a wide range of sources and can be isolated from almost any connective tissue, such as brain, spleen, liver, Kidney, lung, bone marrow, etc. Over the past few decades, researchers have made MSCs the focus of stem ce...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C12N5/0775A61K35/28A61P19/08A61P19/02A61P15/00A61P9/00A61P11/00A61P17/00A61P27/02A61P25/00A61P1/00A61P13/12A61P1/16A61P37/00A61P37/06A61P3/00
CPCC12N5/0662A61K35/28A61P19/08A61P19/02A61P15/00A61P9/00A61P11/00A61P17/00A61P27/02A61P25/00A61P1/00A61P13/12A61P1/16A61P37/00A61P37/06A61P3/00C12N2500/33C12N2500/32C12N2501/115C12N2501/10C12N2501/998A61K35/545C12N5/0663C12N2500/38C12N2500/44C12N5/0665C12N2501/11C12N2501/15A61P7/06A61P19/04A61P17/06A61P21/00A61P25/28A61P13/02A61P17/02A61P25/24A61P15/08A61P25/08A61P25/16A61P29/00C12N2501/165C12N2506/02C12N2506/45
Inventor 周琪胡宝洋郝捷李伟吴骏王柳郭保杰李仲文高婷婷陈燕霞王红梅
Owner BEIJING INST FOR STEM CELL & REGENERATIVE MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products